Notably, insulin treatment (Group L + I) significantly ameliorated cognitive deficits, increasing time spent in the target quadrant (30.03 ± 1.39%, #p < 0.05 vs. Group L) and the frequency of entries into the target location (2.58 ± 0.26, #p < 0.05 vs. Group L) during probe trials. This evidence concerns the gene INS and Cognitive impairment.